The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2
Our results indicate an upregulation in the expression levels of HER2 and EGFR in certain common cancers, suggesting that lapatinib, in addition to breast cancer, could be considered for the treatment of these cancers. Furthermore, we demonstrated that some genes with increased expression in prevalent cancers and associated with poor prognosis have the potential to be modulated by lapatinib.
Authors
- Ali Salehzadeh (ORCID: https://orcid.org/0000-0003-4238-0999)
- Maryam Peymani (ORCID: https://orcid.org/0000-0001-5075-5661)
- Leila Rouhi (ORCID: https://orcid.org/0000-0003-1545-5158)
- Mehrdad Hashemi (ORCID: https://orcid.org/0000-0003-0627-6991)
- Kiavash Hushmandi (ORCID: https://orcid.org/0000-0001-5682-5392)
- Behnaz Dolatabadi
Institutions
- University of Tehran (IR)
- Islamic Azad University Medical Branch of Tehran (IR)
- Biotechnology Research Center (IR)
- Islamic Azad University Rasht Branch (IR)
- Islamic Azad University of Shahrekord (IR)
Publication Details
- Journal
- Molecular and Cellular Probes
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1016/j.mcp.2024.101985
- Citations
- 4
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.13